CTI BioPharma Stock News

CTI BioPharma Corp. (CTIC) with the stream of 5.98% also noticed, India Cellectar Biosciences, Inc. (CLRB) encountered a rapid change of -3.61% in the last hour of trading session. CTI The post Striking Stock: CTI BioPharma Corp. (NASDAQ:CTIC), Cellectar Biosciences, Inc. (NASDAQ:CLRB) appeared first on Stocks Equity .

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-s

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-shortened week. Shares of companies with a COVID portfolio, including a vaccine, a treatment or both, reacted with strong moves to the upside in the truncated session on Friday. Takeda Pharmaceutical Company Limited (NYSE: TAK ) and Aadi Bioscience, Inc. (NASDAQ: AADI ) received Food and Drug Administration nod for their Livtencity and Fyarro, respectively. Here are the catalysts that could impact trading in the upcoming week: Conferences The Evercore ISI 4th Annual HealthCONx Virtual Conference: Nov. 30-Dec. 2 Piper Sandler 33rd Annual Virtual Healthcare Conference: Nov. 29-Dec. 2 American Epilepsy Society, or AES, 2021 Annual Meeting: Dec. 3-7, in Full story available on Benzinga.com

Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.

Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.

Squarepoint Ops LLC reduced its stake in shares of CTI BioPharma Corp. (NASDAQ:CTIC) by 63.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 72,325 shares of the biopharmaceutical companys stock after selling 125,186 shares during the period. Squarepoint Ops LLCs holdings in CTI BioPharma were worth $181,000 as of its most recent SEC []

The trading price of CTI BioPharma Corp. (NASDAQ:CTIC) closed lower on Tuesday, November 23, closing at $2.35, -2.49% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Equities research analysts expect CTI BioPharma Corp. (NASDAQ:CTIC) to announce sales of $27.55 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for CTI BioPharmas earnings. The lowest sales estimate is $3.00 million and the highest is $52.10 million. The company is expected to issue its next earnings report on []

JMP Securities restated their buy rating on shares of CTI BioPharma (NASDAQ:CTIC) in a research note released on Wednesday, TipRanks reports. The firm currently has a $4.00 price objective on the biopharmaceutical companys stock. Other research analysts also recently issued reports about the company. Zacks Investment Research upgraded CTI BioPharma from a sell rating to []

JMP Securities reissued their buy rating on shares of CTI BioPharma (NASDAQ:CTIC) in a research note released on Wednesday, TipRanks reports. The firm currently has a $4.00 price objective on the biopharmaceutical companys stock. CTIC has been the topic of several other research reports. BTIG Research began coverage on CTI BioPharma in a research report []

Brookline Capital Management reiterated their buy rating on shares of CTI BioPharma (NASDAQ:CTIC) in a report issued on Monday, Zacks.com reports. Several other brokerages also recently commented on CTIC. JMP Securities restated a buy rating and set a $4.00 price objective on shares of CTI BioPharma in a research report on Tuesday, August 31st. BTIG []

CTI BioPharma Corp (NASDAQ: CTIC) has announced topline results from the PRE-VENT trial of pacritinib in hospitalized COVID-19 patients. The final PRE-VENT analysis was conducted following the rand

SEATTLE, Oct. 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced topline results from the PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID

SEATTLE, Sept. 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards